EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, IQVIA Holdings's Enterprise Value is $53,748 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2,131 Mil. Therefore, IQVIA Holdings's EV-to-EBIT for today is 25.22.
The historical rank and industry rank for IQVIA Holdings's EV-to-EBIT or its related term are showing as below:
IQV'
s EV-to-EBIT Range Over the Past 10 Years
Min: 13.74 Med: 32.03 Max: 66.77
Current: 25.22
During the past 13 years, the highest EV-to-EBIT of IQVIA Holdings was 66.77. The lowest was 13.74. And the median was 32.03.
IQV's EV-to-EBIT is ranked worse than 61.47% of 109
companies
in the Medical Diagnostics & Research industry
Industry Median: 18.95
vs IQV: 25.22
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. IQVIA Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $54,395 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $2,131 Mil. IQVIA Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.92%.
IQVIA Holdings EV-to-EBIT Historical Data
The historical data trend for IQVIA Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IQVIA Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IQVIA Holdings EV-to-EBIT Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where IQVIA Holdings's EV-to-EBIT falls into.
IQVIA Holdings EV-to-EBIT Calculation
IQVIA Holdings's EV-to-EBIT for today is calculated as:
IQVIA Holdings's current Enterprise Value is $53,748 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,131 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings (NYSE:IQV) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
IQVIA Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $54,395 Mil.
IQVIA Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,131 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IQVIA Holdings EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of IQVIA Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
IQVIA Holdings (IQVIA Holdings) Business Description
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IQV has been successfully added to your 